“Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies” (2009) Hematology Meeting Reports, 1(8). doi:10.4081/hmr.v1i8.297.